J Cardiol’s 2026 Impact Factor is 3.5 Thanks to all of you! Our ranking among journals in the cardiovascular category has also been steadily rising: 92/231 in 2024 → 72/237 in 2025. And best of all, we have “no publication fees” in this day and age, so please do! #JCardiol

#JCardiol 88(4): 244-54, 2026 CT-guided PCI: From diagnosis to treatment planning Highlights 2/3 *CCTA provides anatomical information useful for PCI planning. doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(4): 244-54, 2026 CT-guided PCI: From diagnosis to treatment planning Highlights 1/3 *CT-guided PCI expands the role of CCTA beyond diagnosis. *Integration of CT may enhance procedural understanding before PCI. doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(4): 237-43, 2026 Transcatheter pulmonary valve... Highlights 2/3 *International registries show high procedural success and mid-term durability. *In Japan, SAPIEN 3 and Harmony are approved for distinct anatomical targets. doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(4): 237-43, 2026 Transcatheter pulmonary valve... Highlights 1/3 *TPVI is an established alternative to repeat surgical intervention in repaired TOF. *Self-expanding valves broaden treatable RV outflow tract anatomies. doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(3): 235, 2026 [Letter to the Editors] Interpretive considerations on real-world use of selexipag and parenteral prostacyclin in pulmonary arterial hypertension Fariha Shahid Tanveer, Muhammad Hassan Saeed doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(3): 234, 2026 [Letter to the Editors] Sacubitril/valsartan in older adults: interpreting hypotension, biomarkers, and dose trajectories in routine care Beibei Wang, Yiqun Lou doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(3): 233, 2026 [Letter to the Editors] Selexipag or parenteral prostacyclin? Untangling treatment selection in observational PAH data Abdülmelik Birgün et al doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(3): 231-2, 2026 [Letter to the Editors] Beyond avoidance: The unaddressed analgesic gap in patients with heart failure contraindicated for NSAIDs and COX-2 inhibitors Chia Siang Kow et al doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(3): 229-30, 2026 [Letter to the Editors] Response to letter to the editor Garcia B et al doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(3): 228-9, 2026 [Letter to the Editors] Comments on: “Genotype-phenotype associations in sarcomeric hypertrophic cardiomyopathy associated with mutations in the MYBPC3 gene: Systematic review and meta-analysis” Deng Z et al doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(3): 227, 2026 [Letter to the Editors] Author's reply to “Comment on ‘Cardio-ankle vascular index as a screening tool for coronary artery disease in patients with metabolic dysfunction-associated steatotic... Nakashima M, Miyoshi T doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(3): 226-7, 2026 [Letter to the Editors] Comment on “Cardio-ankle vascular index as a screening tool for coronary artery disease in patients with metabolic dysfunction-associated steatotic liver disease” Harariya K et al doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(3): 223-5, 2026 The frequency and impact of previous admissions within... Highlights 2/3 *Common reasons for prior admission were COVID, sepsis, and myocardial infarction. doi.org/10.1016/j.jjcc.2026.… by A.E. K

#JCardiol 88(3): 223-5, 2026 The frequency and impact of previous admissions within... Highlights 1/3 *12.4% of acute myocarditis admissions were in the prior 90-day period. *Prior admissions were more common among older and comorbid patients. doi.org/10.1016/j.jjcc.2026.… by A.E. K